Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSUMMIT-Jr: Ustekinumab or Guselkumab in Pediatric Juvenile Psoriatic Arthritis
2020-005503-40Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ustekinumab and guselkumab in juvenile psoriatic arthritis (JPsA) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Pharmacokinetics of ustekinumab and Pharmacokinetics of guselkumab. Started Aug 2021; status: active.
02
Drugs
ustekinumabguselkumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on 2020-005503-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005503-40.